Loading component ...

eXciteOSA®

The world’s first clinically1-3 proven daytime therapy for mild sleep apnoea & snoring.

Important information: This is a 20min daytime treatment for Mild Obstructive Sleep Apnoea (OSA) and snoring. Contra-indications can be found in our eXciteOSA User Guide. If you have not yet been diagnosed with sleep apnoea or primary snoring or do not have any written confirmation of a sleep apnoea diagnosis or prior CPAP usage, we recommend seeking medical advice.

Loading component ...

Including postage and packing
Excluding VAT

Loading component ...

Financial support: spread your payments over 6 or up to 36 months with 0% financing from Klarna, e.g. £24.38 per month in 24 monthly instalments, available upon check-out. If you are facing financial hardship in these trying times, contact us and we can help.

Current patients: either ask your Sleep Specialist or contact us to find a specialist familiar with eXciteOSA.
New patients: with no prior diagnosis, contact us to connect you immediately with a Sleep Specialist in your area.

Our in-depth, published clinical trials data suggest that nearly 90% of patients will see significant improvements in the numbers of apnoea and hypopnea events and their snoring.

Financing & Warranties:

  • Interest-free instalments, automatically charged from your card every 30 days
  • No interest or fees when you pay on time
  • Select Klarna at the checkout “payment” stage and enter your credit or debit card
  • Super-simple signup, only available in the UK
  • We stand behind our engineering. Should your product have a defect, we guarantee product performance for up to 12 months

Available to buy in the UK, EU and Canada.

Rest of the World: eXciteOSA® is not yet available for purchase in all countries. In order for us to be able to come back to you once it is available for purchase in your country, please register your interest here.

The eXciteOSA® device will deliver small electric currents through the mouthpiece to your tongue, this will stimulate the tongue muscle and improve its tone. The improved tone of the tongue muscle will help in keeping the breathing passage open during your sleep and reduce the vibration of the throat region.

Contraindications

Do not use eXciteOSA if:

  • You are pregnant or may be pregnant
  • You have a pacemaker or implanted electrodes
  • You have temporary or permanent implants, dental braces or jewellery in your mouth
  • You are suffering from mouth ulceration
  • You have or are suspected of having sleep apnoea with an AHI of greater than 15
  • Safety and effectiveness in the above conditions has not been established.
  • Read all instructions before use

Our eXciteOSA® box includes:

  • Control unit
  • Mouthpiece
  • USB charging cable
  • Quick Start Guide

1. E.Wessoleck et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22(Suppl 2): 47–52.
2. A.Sama et al. Daytime Intraoral Neurostimulation with Snoozeal® for treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes, 2018.
3. Prospective cohort study of 50 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI) <15) with 46 completed the trial. Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period.

Last updated December 2020.

Watch the trailer

how eXciteOSA works - hand with device

With improved sleep quality comes better health, better lives and closer relationships

References

  1. White DP, Sleep-related breathing disorder: 2-pathophysiology of obstructive sleep apnoea. Thorax. 1995; 50:797-804. [PubMed: 7570420]
  2. Peppard PE, Young T, Palta M et al. Prospective study of the association between sleep disordered breathing and hypertension. N Engl J Med 2000; 1378-1384. [PubMEd: 10805822]
  3. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122:352-360. [PubMed: 20625114]
  4. Yaggi HK, Concato J, Kernan WN, et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005;353:2034-2041. [PubMed: 16282178]
  5. Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea-hypopnea and incident stroke: The Sleep Heart Health Study. AM J Respir Crit Care Med. 2010; 182:269-277. [PubMed: 20339144]
  6. Peker Y, Hedner J, Norum J, et al. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. AM J Repir Crit Care Med. 2002; 166:159-165. [PubMed: 12119227]
  7. Marin JM, Carrizo SJ, Vicente E, et al Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005; 365:1046-1053. [PubMed: 15781100]
  8. Peppard PE, Szklo-Coxe M, Hla KM, et al. Longitudinal association of sleep-related breathing disorder and depression. Arch Intern Med. 2006; 166:1709-1715. [PubMed: 16983048]
  9. Kendzerska T, Gershon AS, Hawker G, et al. Obstructive sleep apnea and incident diabetes: a historical cohort study. AM J Respir Crit Care Med. 2014; 190:218-225. [PubMed: 24897551]
  10. E.Wessoleck et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22(Suppl 2): 47–52.
  11. A.Sama et al. Daytime Intraoral Neurostimulation with Snoozeal® for treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes, 2018
  12. Prospective cohort study of 50 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI) <15) with 46 completed the trial. Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period